Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention

Table 1 Incidence of hepatitis B virus replication in hemo-lymphoproliferative diseases and related management, according to hepatitis B virus markers and type of immunosuppressive regimens

Drug classes	Drugs	Incidence of HBVr in the absence of HBV prophylaxis		Management of HBVr
		HBsAg-positive (%)	HBsAg-negative/HBcAb-positive (%)	HBsAg- positive	HBsAg-negative/HBcAb-positive
Monoclonal antibody	Rituximab	High: 30-60	High: > 10	ETV	LMV
	Ofatumumab			TDF
	Obinutuzumab			TAF
	Alemtuzumab
Anthracycline chemotherapy	Doxorubicin	High: 15-30	Moderate: 1-10	ETV	LMV
	Epirubicin Daunorubicin			TDF
				TAF
Tyrosine kinase inhibitors	Imatinib, Nilotinib	Moderate: 1-10	Moderate: 1-10	ETV	LMV
				TDF
	Dasatinib
	Bosutinib
	Ponatinib			TAF
Proteasome inhibitors	Bortezomib	Moderate: 1-10	Moderate: 1-10	ETV	LMV
	Carfilzomib			TDF
	Ixazomib			TAF
Inhibitors of cytokine	Mogamulizumab	Moderate: 1-10	Moderate: 1-10	ETV	LMV
				TDF
				TAF
Corticosteroids	High/moderate dose of prednisone	High: > 10	Moderate: 1-10	ETV	LMV
				TDF
				TAF

HBV: Hepatitis B virus; HBVr: Hepatitis B virus replication; HbsAg: Hepatitis B surface antigen; HbcAb: Hepatitis B core antibodies; ETV: Entecavir; TDF: Tenofovir; TAF: Tenofovir alafenamide; LMV: Lamivudine.